Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Phil Nadeau
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters; questions recorded in 5).
- Questions
- 8on tracked calls
- Challenge rate
- 38%3 of 8 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 5with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 8 of 8 questions from 2 companies
VRTXVertex Pharmaceuticals5 questions · 4 reporting periods · 1 of 5 challenging
Calendar 2026 Q2
Is there a level of sweat chloride reduction that would get your attention
Show response
Reshma: the bar is getting more patients below 30 mmol sweat chloride, where ALYFTREK already reaches ~2/3; exact reduction matters less.
Calendar 2025 Q4
could you give us some sense of the breakdown between KESJEVRI and Genomics in that number
Show response
Charlie declined to break down CASGEVY vs JOURNAVX within the $500M+ non-CF guide but cited visibility from 300+ patient initiations and 150+ cell collections for CASGEVY, plus expected tripling of JOURNAVX prescriptions with better revenue conversion from expanded access.
Calendar 2025 Q3
Can you give us a sense of where it currently is and where it could be in 2026
Show response
Charlie acknowledged elevated gross-to-net driven by active patient support program but declined to provide 2026 guidance until payer mix and contracting are finalized.
Calendar 2024 Q4
can you give us some sense of will the prescription data that we see from third-party sources be accurate
Show response
Stuart noted retail prescription data is robust but hospital data is volume-based. Vertex will provide prescription and covered lives updates throughout 2025.
on ALYFTREK, there is a dispute going on between you and Royalty Pharma as to exactly what Royalty is owed
Show response
Reshma dismissed the dispute framing, stating the contractual agreement clearly spells out responsibilities and she sees no room for interpretation.
BIIBBiogen3 questions · 3 reporting periods · 2 of 3 challenging
Calendar 2025 Q4
When do you think the growth products could overtake the legacy franchises
Show response
Chris noted full-year TECFIDERA erosion and TYSABRI biosimilar as headwinds. Growth inflection tied to Phase 3 readouts and launches: litifilimab SLE and felzartamab AMR potentially launching 2028. AMR could take off quickly given identified patient base and no existing treatment. BD target around $5-6B for post-Phase 3 companies but discipline on valuation.
Calendar 2025 Q2
Could you remind us whether there's a similar interim in AHEAD 3-45 and maybe more broadly discuss the differences in design between AHEAD 3-45 and TRAILBLAZER-ALZ 3
Show response
Priya detailed key design differences: AHEAD used amyloid PET screening with CDR 0 (no cognitive decline) vs competitor's mixed criteria including CDR 0.5 and 1. Different endpoints (preclinical AD composite vs CDR). Readout 2028 with optionality reserved for interim.
Calendar 2024 Q4
In Q4, revenue was up 30%, but the revenue recognized was only up $1 million. Can you talk about the dynamics behind that?
Show response
Chris pivoted to 2025 outlook rather than directly addressing the recognized vs in-market revenue gap. Noted steady quarterly progress expected with potential acceleration from subcutaneous formulation.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| VRTX Vertex Pharmaceuticals | 5 | 20%1 of 5 questions |
| BIIB Biogen | 3 | 67%2 of 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 3 | 33%1 of 3 questions | 2 |
| 2025 Q1 | No questions recorded | — | — |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | 2 | 50%1 of 2 questions | 2 |
| 2026 Q1 | No questions recorded | — | — |
| 2026 Q2 | 1 | 100%1 of 1 question | 1 |
- 2024 Q43 questions · challenge rate 33% (1 of 3 questions) · 2 companies
- 2025 Q1No questions recorded
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q42 questions · challenge rate 50% (1 of 2 questions) · 2 companies
- 2026 Q1No questions recorded
- 2026 Q21 question · challenge rate 100% (1 of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Product Launch4
- Revenue Growth3
- Competitive Dynamics2
- Innovation & R&D2
- Margin2
- M&A1
- Regulation Policy1